AB1306 HOW DOES COVID-19 VACCINATION AFFECT DISEASE ACTIVITY AND SAFETY IN SECUKINUMAB TREATED PATIENTS WITH AXIAL SPONDYLOARTHRITIS? REAL WORLD DATA FROM THE GERMAN AQUILA STUDY

Background Patients (pts) suffering from a chronic rheumatic condition, such as axial spondyloarthritis (axSpA), and receiving immunosuppressive treatment during the COVID-19 pandemic have been shown to be at higher risk of severe disease outcomes. The German non-interventional study AQUILA provides real-world data in pts with axSpA under secukinumab (SEC) influence vaccination on activity (DA) safety [1]. Objectives aim this interim analysis was describe selected baseline (BL) characteristics effect DA pts. Methods is an ongoing, multi-center including up 3000 or psoriatic arthritis. This focuses included May 2019 Oct 2022 their status (no vs ≥1 vaccination) for time points BL week (w) 52 according clinical routine. assessed by validated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questionnaire documented number (serious) adverse events (S)AEs). Only available BASDAI were considered characterized parameters, demographics global functioning (measured assessment international society health Index, ASAS-HI). Real-world analyzed observed. Vaccination performed prescription took place any timepoint throughout observational period weeks. Results Totally, 273 included. For 56 documented: vaccinations (75% mRNA-based): n1 = 26 pts, n2 20 n3 9 n4 1 pt. Both groups comparable regarding characteristics, age, smoking status, BMI, physician (PhGA), ASAS-HI. Pts no received less pretreatments biologics (59.9% 76.8%) affected comorbidities extra-articular manifestations (EAMs) than (e.g. depression 6.5% 12.5%) (Table 1). There difference mean between weeks (except value w16). In both groups, slight improvement observed over vaccination: 5.1 3.8, 5.4 3.7) (Figure However, due different numbers vaccination, must interpreted carefully. AEs leading interruption SEC lower (62.7% 75.0% 13.4% 17.9%, respectively) 1), new unexpected signals each group. Conclusion setting, differences without improved similarly w52 patient similar though more comorbidities/EAMs vaccination. groups. Further progress will reveal whether trend confirmed patients Reference [1]Deodhar A, et al., ACR Poster (#1776), Arthritis Rheumatol 2022; 74 (suppl 9) Table 1. Overview (S)AEs Parameters No (N=217) (N=56) Age* (years) 47.1 (13.5) 46.7 (13.0) Smoking (smoker)** 73 (33.8) 19 (33.9) BMI* (kg/m 2 ) 27.4 (5.6) 27.5 (5.4) PhGA* 5.3 (2.0) 5.0 ASAS-HI* 7.5 (3.4) 8.6 (3.5) Pre-treatment biologics** 130 (59.9) 43 (76.8) Comorbidities/EAMs** Coronary heart 10 (4.7) 3 (5.3) Heart insufficiency (1.4) (3.6) Stroke (1.0) (1.8) Plaque psoriasis (9.2) 7 (12.5) Uveitis 6 (2.7) Depression 14 (6.5) Safety - pts** AEs/ SAEs 136 (62.7)/ 13 (6.0) 42 (75.0)/ 5 (8.9) 29 (13.4) (17.9) * (sd), ** n (%) Figure stratified Acknowledgements: NIL. Disclosure Interests Jan Brandt-Juergens Consultant of: Abbvie, Affibody, BMS, Gilead, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB, Karolina Gente Speakers bureau: AbbVie, Gilead/Galapagos, Hexal/Sandoz, Viatris, Grant/research support from: Mundipharma, Peter Kästner Chugai, Daniel Peterlik Employee Novartis Pharma GmbH, Uta Kiltz Amgen, Biogen, Eli GSK, Grünenthal, Hexal, Prizer, MDS, USB.